Safety and Efficacy of Intraperitoneal Paclitaxel Plus Intravenous Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX) for Gastric Cancer with Peritoneal Metastasis

Min, Sa Hong; Kim, Jin Won; Lee, Eun‐Ju; Park, Sang Woo; Lee, Sang-Jun; Oh, Hyeon Jeong; Park, Young Suk; Lee, Yoon Jin; Kim, Jiwon; Ahn, Sang-Hoon; Suh, Yun-Suhk; Lee, Keun-Wook; Lee, Hye Seung; Kim, Hyung‐Ho

doi:10.1245/s10434-022-11582-5

Cited by 10 publications

(4 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…histology Paclitaxel at days 1, 8 and 22 in 5-week cycles Cisplatin + S-1 Not reached 20 mg/m 2 None Kim et al, 2021 [ 92 ] 4 9 Pos. histology Paclitaxel at days 1 and 8 in 3-week cycles Oxaliplatin + S-1 Not reached 80 mg/m 2 None Kang et al, 2022 [ 93 ] 4 15 Pos. histology Paclitaxel at days 1 and 8 in 3-week cycles 5-FU, leucovorin and oxaliplatin 80 mg/m 2 60 mg/m 2 Febrile neutropenia grade 3 Cho et al, 2017 [ 73 ] 4 12 Pos.…”

Section: Results Of Intraperitoneal Chemotherapy For Unresectable Per...mentioning

confidence: 99%

“…However, a retrospective analysis on intraperitoneal paclitaxel showed that the type of systemic chemotherapy did not influence overall survival [86]. In Phase I studies, intraperitoneal paclitaxel in combination with several types of systemic chemotherapy resulted in recommended doses between 20 and 80 mg/m 2 , depending on the frequency of administration [87][88][89][90][91][92][93]. The most common dose-limiting toxicities (DLTs) were hematological disorders (mostly neutropenia) or gastro-intestinal toxicities such as diarrhea or vomiting.…”

Section: Gastric Cancermentioning

confidence: 99%

See 1 more Smart Citation

Intraperitoneal Chemotherapy for Unresectable Peritoneal Surface Malignancies

Guchelaar

Noordman

Koolen

et al. 2023

Drugs

View full text Add to dashboard Cite

Malignancies of the peritoneal cavity are associated with a dismal prognosis. Systemic chemotherapy is the gold standard for patients with unresectable peritoneal disease, but its intraperitoneal effect is hampered by the peritoneal-plasma barrier. Intraperitoneal chemotherapy, which is administered repeatedly into the peritoneal cavity through a peritoneal implanted port, could provide a novel treatment modality for this patient population. This review provides a systematic overview of intraperitoneal used drugs, the performed clinical studies so far, and the complications of the peritoneal implemental ports. Several anticancer drugs have been studied for intraperitoneal application, with the taxanes paclitaxel and docetaxel as the most commonly used drug. Repeated intraperitoneal chemotherapy, mostly in combination with systemic chemotherapy, has shown promising results in Phase I and Phase II studies for several tumor types, such as gastric cancer, ovarian cancer, colorectal cancer, and pancreatic cancer. Two Phase III studies for intraperitoneal chemotherapy in gastric cancer have been performed so far, but the results regarding the superiority over standard systemic chemotherapy alone, are contradictory. Pressurized intraperitoneal administration, known as PIPAC, is an alternative way of administering intraperitoneal chemotherapy, and the first prospective studies have shown a tolerable safety profile. Although intraperitoneal chemotherapy might be a standard treatment option for patients with unresectable peritoneal disease, more Phase II and Phase III studies focusing on tolerability profiles, survival rates, and quality of life are warranted in order to establish optimal treatment schedules and to establish a potential role for intraperitoneal chemotherapy in the approach to unresectable peritoneal disease. Supplementary Information The online version contains supplementary material available at 10.1007/s40265-022-01828-7.

show abstract

Section: Results Of Intraperitoneal Chemotherapy For Unresectable Per...mentioning

confidence: 99%

Section: Gastric Cancermentioning

confidence: 99%

Intraperitoneal Chemotherapy for Unresectable Peritoneal Surface Malignancies

Guchelaar

Noordman

Koolen

et al. 2023

Drugs

View full text Add to dashboard Cite

show abstract

“…This study seems to have a better design than the PHOENIX-GC study owing to the homogeneity of the drugs used and the endpoints considered (pathological response and the rate of conversion surgery). However, the inclusion criteria are unclear given that they do not take into consideration a cutoff in the PCI, the extent of ascites, or HER2 status, which is considered by many authors as an exclusion criterion for NIPS treatment [ 30 , 49 , 50 ].…”

Section: Neoadjuvant Chemotherapy For Patients With Gc and Synchronou...mentioning

confidence: 99%

Gastric Cancer (GC) with Peritoneal Metastases (PMs): An Overview of Italian PSM Oncoteam Evidence and Study Purposes

Sammartino

Manzoni

Marano

et al. 2023

Cancers

View full text Add to dashboard Cite

Gastric cancer (GC) continues to be one of the leading types of malignancies worldwide, despite an ongoing decrease in incidence. It is the fifth most frequent type of cancer in the world and the fourth leading cause of cancer death. Peritoneal metastases (PMs) occur in 20–30% of cases during the natural history of the disease. Systemic chemotherapy (SC) is undoubtedly the standard of care for patients with GC and PMs. However, with the development of highly effective regimens (SC combined with intraperitoneal chemotherapy), significant tumor shrinkage has been observed in many patients with synchronous GC and PMs, allowing some to undergo curative resection “conversion surgery” with long-term survival. In recent years, there has been growing interest in intraperitoneal chemotherapy for PMs, because the reduced drug clearance associated with the peritoneal/plasma barrier allows for direct and prolonged drug exposure with less systemic toxicity. These procedures, along with other methods used for peritoneal surface malignancies (PSMs), can be used in GCs with PMs as neoadjuvant chemotherapy or adjuvant treatments after radical surgery or as palliative treatments delivered either laparoscopically or—more recently—as pressurized intraperitoneal aerosol chemotherapy. The great heterogeneity of patients with stage IV gastric cancer did not allow us to carry out a systemic review; therefore, we limited ourselves to providing readers with an overview to clarify the indications and outcomes of integrated treatments for GCs with PMs by analyzing reports from the international clinical literature and the specific experiences of our oncoteam.

show abstract

“…Previous studies have suggested that chemotherapy drugs including taxane, LBP, and tegafur have good efficacy and safety in the treatment of gastric cancer ( 24 - 26 ). While these agents can be used in combination, there is current no relevant data on the combined used of all three chemotherapy drugs.…”

Section: Introductionmentioning

confidence: 99%

A small-scale, exploratory real-world study of nab-paclitaxel combined with oxaliplatin and tegafur in the perioperative treatment of advanced gastric cancer: a study protocol for a real-world clinical trial

Zheng¹,

Wang²,

Xu³

et al. 2023

J Gastrointest Oncol

View full text Add to dashboard Cite

Background Nanoparticle albumin-bound paclitaxel (nab-paclitaxel) is an optimized and improved derivative of paclitaxel with superior efficacy and fewer adverse reactions, and it is widely used in the treatment of advanced gastric cancer. However, there is a paucity of data regarding the safety and efficacy of nab-paclitaxel combined with oxaliplatin (LBP) and tegafur in the treatment of patients with advanced gastric cancer. Methods This analysis is a prospective, single-center, open-label, historically controlled real-world study designed to include 10 patients with advanced gastric cancer treated with nab-paclitaxel combined with LBP and tegafur gimeracil oteracil potassium. The primary and main efficacy outcomes are safety indicators, including the incidence of adverse drug reactions and adverse events (AEs), as well as the outliers of laboratory indicators and vital signs. The secondary efficacy outcomes are overall survival (OS), objective response rate (ORR), disease control rate (DCR), and proportion of dose suspensions, dose reductions and discontinuations. Discussion Based on the findings of previous studies, we wished to assess the safety and efficacy of nab-paclitaxel combined with LBP and tegafur in the treatment of advanced gastric cancer. The trial requires constant contact and monitoring. The purpose is to determine a superior protocol in terms of patient survival, and pathological and objective response. Trial Registration This trial has been registered with the Clinical Trial Registry: NCT05052931 (registration date: 2021/9/12).

show abstract

Safety and Efficacy of Intraperitoneal Paclitaxel Plus Intravenous Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX) for Gastric Cancer with Peritoneal Metastasis

Cited by 10 publications

References 22 publications

Intraperitoneal Chemotherapy for Unresectable Peritoneal Surface Malignancies

Intraperitoneal Chemotherapy for Unresectable Peritoneal Surface Malignancies

Gastric Cancer (GC) with Peritoneal Metastases (PMs): An Overview of Italian PSM Oncoteam Evidence and Study Purposes

A small-scale, exploratory real-world study of nab-paclitaxel combined with oxaliplatin and tegafur in the perioperative treatment of advanced gastric cancer: a study protocol for a real-world clinical trial

Contact Info

Product

Resources

About